Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries
about
Protein adducts as prospective biomarkers of nevirapine toxicity.Quinone Methide Bioactivation Pathway: Contribution to Toxicity and/or Cytoprotection?Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine.The role of the immune system in nevirapine-induced subclinical liver injury of a rat model.Bioactivation of nevirapine to a reactive quinone methide: implications for liver injury.Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism.Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population.Overview of metabolite safety testing from an industry perspective.NMR spectroscopy as a tool to close the gap on metabolite characterization under MIST.From definition to implementation: a cross-industry perspective of past, current and future MIST strategies.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.The early estimation of circulating drug metabolites in humans.The generation, detection, and effects of reactive drug metabolites.Biotransformation and bioactivation reactions - 2016 literature highlights.Potential roles of myeloperoxidase and hypochlorous acid in metabolism and toxicity of alkene hydrocarbons and drug molecules containing olefinic moieties.Modeling Epoxidation of Drug-like Molecules with a Deep Machine Learning Network.Evaluation of the metabolism, bioactivation and pharmacokinetics of triaminopyrimidine analogs toward selection of a potential candidate for antimalarial therapy.Formation of A Novel Purine Metabolite through CYP3A4 Bioactivation and Glutathione ConjugationIntegrated systems for quantifying metabolite biomarkers of hepatic bioactivation in patients.Synthesis and oxidation of 2-hydroxynevirapine, a metabolite of the HIV reverse transcriptase inhibitor nevirapine.2'-Deoxythymidine adducts from the anti-HIV drug nevirapine.Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions.Hepatocyte spheroids as a competent in vitro system for drug biotransformation studies: nevirapine as a bioactivation case study.
P2860
Q33681307-2D990187-BC2B-4D9F-A4D4-A3DAC93D64A5Q34378297-88B5C8C8-63B5-4F51-9693-A4200A258867Q34794696-6FA24192-7D12-4A0D-AABC-E6CA597CE9D6Q36200176-ACFFAE51-7DDF-40BC-9819-4AA96A78BA3DQ36330185-087B658F-AEC6-41B3-BFC0-9B051A5C7D1CQ36553553-60C27C83-B1B4-4837-AA7B-B0299037FC5BQ36740238-77F41AEA-07FC-48FC-B6D7-226CB30F2A27Q37810227-D0385AC5-93EF-4E42-810A-8C2E9F7643CCQ37810228-E51C0607-462E-4374-BF74-2FBFACC35DB1Q37859007-F3A60788-1596-46DC-95A5-878BA10529DDQ37866298-F07E78B0-A01E-4D51-B41D-523DB1F9FCF4Q38017286-38E1EEDD-7C81-47E1-A2C3-1CC4AC3E3E6EQ38054629-B0040C20-46E0-491C-99FB-3AF0D0B31A87Q38688045-444FDAF6-E0CA-4DFF-9405-0BE75691A2B1Q39034440-C9D84502-E005-40B8-A9F1-BD1B45E3B4D5Q40028855-9C410FC9-792E-4942-B22D-707B44225D71Q40501587-C6524B1A-02E9-420A-ABDF-8C44A1A8B82CQ42290476-1C6EF63C-0781-418E-9D8F-75A84794F149Q42807068-41CFEDF3-27EA-4571-8919-B945C0FDF43EQ43484802-F17C432B-0241-4A4A-8286-C4C124660140Q46731348-A1CC2CAC-B975-4E00-BC2D-02E173C93DAFQ51202282-5C660DFC-D6D7-494B-AE2D-33FB75D4DACFQ51641157-22D2EDCA-FA0A-4A53-BAB3-4ED19B4EA909
P2860
Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Quantifying the metabolic acti ...... of NMR and mass spectrometries
@ast
Quantifying the metabolic acti ...... of NMR and mass spectrometries
@en
Quantifying the metabolic acti ...... f NMR and mass spectrometries.
@nl
type
label
Quantifying the metabolic acti ...... of NMR and mass spectrometries
@ast
Quantifying the metabolic acti ...... of NMR and mass spectrometries
@en
Quantifying the metabolic acti ...... f NMR and mass spectrometries.
@nl
prefLabel
Quantifying the metabolic acti ...... of NMR and mass spectrometries
@ast
Quantifying the metabolic acti ...... of NMR and mass spectrometries
@en
Quantifying the metabolic acti ...... f NMR and mass spectrometries.
@nl
P2093
P2860
P356
P1476
Quantifying the metabolic acti ...... of NMR and mass spectrometries
@en
P2093
Abhishek Srivastava
B Kevin Park
James L Maggs
Lu-Yun Lian
Masautso Chaponda
P2860
P304
P356
10.1124/DMD.109.028688
P577
2010-01-01T00:00:00Z